CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS);INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE);Institut Curie;Sebastian AMIGORENA;Eliane PIAGGIO;Christel GOUDOT;Luigia PACE;Gen
发明人:
Sebastian AMIGORENA,Eliane PIAGGIO,Christel GOUDOT,Luigia PACE,Genevieve ALMOUZNI
申请号：
IL27161819
公开号：
IL271618D0
申请日:
2019.12.19
申请国别(地区):
IL
年份:
2020
代理人:
摘要：
The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell； and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.
